TY - JOUR
T1 - Protein kinase C pathway is involved in regulating the secretion of prostatic acid phosphatase in human prostate cancer cells
AU - Lin, Ming Fong
AU - Zhang, Xiu Qing
AU - Dean, Jeanenne
AU - Lin, Fen Fen
N1 - Funding Information:
This was supported in part by CA 72274, CA88184 from NCI, NIH, the Nebraska Department of Health LB595, and the BMB Prostate Cancer Research Fund. We thank Ms Renee Garcia-Arenas and Dr Tzu-Ching Meng for technical support, discussions and help in organizing graphs in the early phase of the studies.
PY - 2001
Y1 - 2001
N2 - The stimulated secretion of prostatic acid phosphatase (PAcP) has been known to be a hallmark of androgen action on human prostate epithelial cells for the last five decades. The molecular mechanism of androgen action on PAcP secretion, however, has remained mostly unknown. We investigated the molecular mechanism that promotes PAcP secretion in LNCaP human prostate carcinoma cells which express PAcP and are androgen-responsive. Treatment with 12-o-tetradecanoyl phorbol-13-acetate (TPA), a protein kinase C (PKC) activator, resulted in an increased secretion of PAcP in a dose- and time-dependent fashion. 4α-Phorbol, a biologically inactive isomer of TPA, had no effect. This TPA stimulation of PAcP secretion was observed 2 h after exposure, while TPA did not have a significant effect on the mRNA level even with a 6 h treatment. A23187 calcium ionophore, known to mobilize cellular calcium which is a co-factor of PKC, also activated PAcP secretion. This TPA stimulation of PAcP secretion was more potent than the conventional stimulating agent 5α-dihydrotestosterone (DHT) at the same concentration of 50 nM. Furthermore, the action of TPA and DHT on PAcP secretion was blocked by five different PKC inhibitors. Results also showed that DHT, as well as TPA, could rapidly modulate PKC activity. Therefore, PKC can regulate PAcP secretion, and may also be involved in DHT action on PAcP secretion.
AB - The stimulated secretion of prostatic acid phosphatase (PAcP) has been known to be a hallmark of androgen action on human prostate epithelial cells for the last five decades. The molecular mechanism of androgen action on PAcP secretion, however, has remained mostly unknown. We investigated the molecular mechanism that promotes PAcP secretion in LNCaP human prostate carcinoma cells which express PAcP and are androgen-responsive. Treatment with 12-o-tetradecanoyl phorbol-13-acetate (TPA), a protein kinase C (PKC) activator, resulted in an increased secretion of PAcP in a dose- and time-dependent fashion. 4α-Phorbol, a biologically inactive isomer of TPA, had no effect. This TPA stimulation of PAcP secretion was observed 2 h after exposure, while TPA did not have a significant effect on the mRNA level even with a 6 h treatment. A23187 calcium ionophore, known to mobilize cellular calcium which is a co-factor of PKC, also activated PAcP secretion. This TPA stimulation of PAcP secretion was more potent than the conventional stimulating agent 5α-dihydrotestosterone (DHT) at the same concentration of 50 nM. Furthermore, the action of TPA and DHT on PAcP secretion was blocked by five different PKC inhibitors. Results also showed that DHT, as well as TPA, could rapidly modulate PKC activity. Therefore, PKC can regulate PAcP secretion, and may also be involved in DHT action on PAcP secretion.
KW - Androgen regulation
KW - Human prostate cancer cells
KW - Prostatic acid phosphatase
KW - Protein kinase C
UR - http://www.scopus.com/inward/record.url?scp=0035212952&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035212952&partnerID=8YFLogxK
U2 - 10.1006/cbir.2001.0794
DO - 10.1006/cbir.2001.0794
M3 - Article
C2 - 11913958
AN - SCOPUS:0035212952
SN - 1065-6995
VL - 25
SP - 1139
EP - 1148
JO - Cell Biology International
JF - Cell Biology International
IS - 11
ER -